Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNISA VENTURES PTY LTD has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single case is assigned to 1 distinct art unit, reflecting a focused technical review process for the company. This concentration in 1 art unit allows the applicant to navigate the specific procedural norms and technical expectations of that administrative group within the biotechnology sector.
The busiest examiner for the portfolio is HELM, CARALYNNE E, who is overseeing the 1 pending office action. Because there is only 1 distinct examiner, the company's immediate prosecution outcomes are dependent on the feedback from this specific examiner. This relationship with HELM, CARALYNNE E is the central element of the company's current patent office interactions.
With 1 pending office action currently active, the company's immediate patent strategy is tied to the resolution of this 1 matter. The 1 distinct art unit involved provides a singular technical context for the review of the company's pharmaceutical claims. Practitioners should prioritize the specific concerns of the 1 assigned examiner to ensure the application progresses effectively through the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539645 | METHOD AND COMPOSITION FOR DELIVERING A COMPOUND THROUGH A BIOLOGICAL BARRIER | HELM, CARALYNNE E | 98d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539645 | METHOD AND COMPOSITION FOR DELIVERING A COMPOUND THROUGH A BIOLOGICAL BARRIER | HELM, CARALYNNE E | 98d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18539645 | METHOD AND COMPOSITION FOR DELIVERING A COMPOUND THROUGH A BIOLOGICAL BARRIER | HELM, CARALYNNE E | 1615 | §103§112DP | Final Rejection | 98d overdue | Pending | Dec 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNISA VENTURES PTY LTD has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Caralynne E Helm has the most, with 1 of UNISA VENTURES PTY LTD's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
